Catalyst Funds Management’s Guardant Health GH Stock Holding History

Catalyst Funds Management’s Portfolio GH Stock Details GH Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$11M	Buy	+73,300	New	+$7.97M	0.62%	31

Other funds holding GH

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Invesco Atlanta, Georgia $1.26T AUM 61.52% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return

DTC

Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Catalyst Funds Management's GH Position: Q2 2026 in Review

Catalyst Funds Management opened a new position in Guardant Health (GH) in Q2 2026: 73,300 shares worth $11M. The stake represents 0.62% of the portfolio and ranks #31 among its holdings.

597 funds tracked by Wall St. Rank hold GH as of Q2 2026.

Catalyst Funds Management held 73,300 shares of Guardant Health worth $11M as of Q2 2026.
Guardant Health was a new Catalyst Funds Management position in Q2 2026.
Guardant Health made up 0.62% of Catalyst Funds Management's portfolio in Q2 2026, its #31 holding.
597 funds tracked by Wall St. Rank held Guardant Health as of Q2 2026.

Based on Catalyst Funds Management's 13F filing for Q2 2026, filed 10 Aug 2026.